LIPID METABOLISM DISORDERS IN PATIENTS WITH CHRONIC KIDNEY DISEASE INFECTED WITH COVID-19
DOI:
https://doi.org/10.5281/zenodo.17311935Abstract
COVID-19 infection affects the entire body, including metabolic processes. In patients with chronic kidney disease (CKD), lipid metabolism is already impaired, and this condition tends to worsen in the presence of COVID-19. Dyslipidemia is one of the main risk factors for complications in CKD patients and has particular clinical significance during COVID-19 infection.
References
1.Li Y., et al. (2020). Lipid metabolism and its implications in COVID-19 pathogenesis and therapeutics. Journal of Clinical Lipidology, 14(5): 622–630.
2.Ahmadpoor P., Rostaing L. (2020). Why the immune system fails to mount an adaptive immune response to a COVID-19 infection in kidney patients. Transplant International, 33(7): 824–825.
3.Stenvinkel P., et al. (2018). Inflammation and dyslipidemia in chronic kidney disease: what can we learn from experimental models? Kidney International Supplements, 8(1): 18–23.
4.Kwan B.C.H., et al. (2019). Lipid disorders in chronic kidney disease. Journal of Nephrology, 32(6): 671–679.
5.Zhou F., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 395(10229): 1054–1062.
6.KDIGO Clinical Practice Guidelines for Lipid Management in CKD (2021). Kidney Disease: Improving Global Outcomes (KDIGO). Available at: www.kdigo.org
